BR0312691A - Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo - Google Patents
Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmoInfo
- Publication number
- BR0312691A BR0312691A BR0312691-9A BR0312691A BR0312691A BR 0312691 A BR0312691 A BR 0312691A BR 0312691 A BR0312691 A BR 0312691A BR 0312691 A BR0312691 A BR 0312691A
- Authority
- BR
- Brazil
- Prior art keywords
- ligand
- fbkp
- collection
- recombinant
- strain
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 230000001851 biosynthetic effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229930001119 polyketide Natural products 0.000 abstract 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 abstract 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000003881 polyketide derivatives Chemical class 0.000 abstract 1
- 125000000830 polyketide group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0216509A GB0216509D0 (en) | 2002-07-16 | 2002-07-16 | Production of polyketides and other natural products |
| GB0224922A GB0224922D0 (en) | 2002-10-25 | 2002-10-25 | Production of polyketides and other natural products |
| PCT/GB2003/003230 WO2004007709A2 (en) | 2002-07-16 | 2003-07-16 | Production of polyketides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312691A true BR0312691A (pt) | 2005-05-10 |
Family
ID=30117119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312691-9A BR0312691A (pt) | 2002-07-16 | 2003-07-16 | Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7300942B2 (enExample) |
| EP (5) | EP1589031B1 (enExample) |
| JP (5) | JP2005532809A (enExample) |
| CN (1) | CN100569944C (enExample) |
| AT (1) | ATE370161T1 (enExample) |
| AU (1) | AU2003246965B2 (enExample) |
| BR (1) | BR0312691A (enExample) |
| CA (1) | CA2492153C (enExample) |
| CY (1) | CY1107764T1 (enExample) |
| DE (1) | DE60315723T2 (enExample) |
| DK (1) | DK1589031T3 (enExample) |
| ES (2) | ES2544624T3 (enExample) |
| MX (1) | MXPA05000139A (enExample) |
| PT (1) | PT1589031E (enExample) |
| WO (1) | WO2004007709A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2492153C (en) * | 2002-07-16 | 2012-05-08 | Biotica Technology Limited | Production of polyketide fkbp-ligand analogues |
| KR20060085246A (ko) | 2003-09-18 | 2006-07-26 | 마커사이트, 인코포레이티드 | 경공막 전달 |
| CN1946852A (zh) * | 2004-04-27 | 2007-04-11 | 惠氏公司 | 利用雷帕霉素特异性甲基化酶标记雷帕霉素 |
| MXPA06014080A (es) * | 2004-06-03 | 2007-02-15 | Wyeth Corp | Agregado de genes biosinteticos para la produccion de un policetido complejo. |
| GB0417852D0 (en) * | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
| NZ574663A (en) | 2004-12-20 | 2010-05-28 | Wyeth Corp | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| RU2007119585A (ru) | 2004-12-20 | 2009-01-27 | Вайет (Us) | Производные рапамицина и их применение при лечении неврологических заболеваний |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| NZ561647A (en) * | 2005-03-11 | 2011-01-28 | Biotica Tech Ltd | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| WO2006095173A2 (en) * | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| KR20140093764A (ko) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| GB0609963D0 (en) | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| KR100750810B1 (ko) | 2006-08-07 | 2007-08-22 | 동국제약 주식회사 | 스트렙토마이세스 히그로스코피쿠스 ａｔｃｃ １４８９１변이주 및 이를 이용한 타크로리무스 생산 방법 |
| DK2142638T3 (en) * | 2007-04-02 | 2016-12-12 | Newsouth Innovations Pty Ltd | Process for the production of secondary metabolites |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
| US8921642B2 (en) * | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| CN102224242B (zh) | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| GB0904540D0 (en) | 2009-03-17 | 2009-04-29 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0914589D0 (en) | 2009-08-20 | 2009-09-30 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| RU2013128448A (ru) | 2010-12-08 | 2015-01-20 | Осло Юниверсити Хоспитал Хф | Производные триазола в качестве ингибиторов сигнального пути wnt |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
| US20150073043A1 (en) * | 2012-01-19 | 2015-03-12 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Use of phosphorylation pathway-related factor in regulating function of regulatory t cell |
| KR101331491B1 (ko) | 2012-03-21 | 2013-11-20 | 이화여자대학교 산학협력단 | 증가된 라파마이신 생성능을 갖는 신규 미생물 균주 |
| GB201312318D0 (en) | 2013-07-09 | 2013-08-21 | Isomerase Therapeutics Ltd | Novel methods and compounds |
| EP3341381A4 (en) * | 2015-08-28 | 2019-06-12 | Buck Institute for Research on Aging | RAPAMYCIN ANALOGUE WITH IMPROVED MTORC1 SPECIFICITY |
| JP2020507632A (ja) | 2017-02-10 | 2020-03-12 | マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. | ラパマイシン類似体 |
| WO2019157363A2 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of cancer |
| WO2019157374A1 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of neurodegenerative conditions |
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| CN115125179B (zh) * | 2021-03-26 | 2023-10-27 | 上海医药工业研究院 | 产雷帕霉素的基因工程菌及其应用 |
| US20230104503A1 (en) * | 2021-06-25 | 2023-04-06 | The Regents Of The University Of California | Small molecule compounds |
| US20240376122A1 (en) * | 2021-06-25 | 2024-11-14 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| SE416705B (sv) | 1978-02-27 | 1981-02-02 | Torsten & Andersson Kaj | Anordning for utskjutning av bollar |
| GB2165090A (en) | 1984-09-26 | 1986-04-03 | Philips Electronic Associated | Improving the field distribution in high voltage semiconductor devices |
| JPS6453991A (en) | 1987-08-25 | 1989-03-01 | Mitsubishi Electric Corp | Magazine-cum-reel |
| US5109112A (en) | 1989-01-19 | 1992-04-28 | Merck & Co., Inc. | FK-506 cytosolic binding protein |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
| WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
| US5093338A (en) * | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5091389A (en) | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
| CA2102116A1 (en) | 1991-05-31 | 1992-12-01 | Gary R. Schulte | Use of rapamycin prodrugs as immunosuppressant agents |
| US5763590A (en) | 1991-10-11 | 1998-06-09 | Vertex Pharmaceuticals, Inc. | Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA |
| GB9125660D0 (en) * | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| US5498597A (en) | 1992-01-17 | 1996-03-12 | Dana-Farber Cancer Institute, Inc. | FKBP-13, an FK506-binding immunophilin |
| JP3140228B2 (ja) | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB9302569D0 (en) | 1993-02-10 | 1993-03-24 | Smithkline Beecham Plc | Novel compound |
| US5354845A (en) | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
| GB9315914D0 (en) * | 1993-07-31 | 1993-09-15 | Smithkline Beecham Plc | Novel compound |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| UA41884C2 (uk) * | 1993-11-05 | 2001-10-15 | Амерікан Хоум Продактс Корпорейшн | Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів |
| CA2175215C (en) * | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US5457182A (en) | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| ATE286133T1 (de) | 1995-07-06 | 2005-01-15 | Univ Leland Stanford Junior | Zellfreie synthese von polyketiden |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| GB9710962D0 (en) | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
| ES2244001T3 (es) | 1996-07-05 | 2005-12-01 | Biotica Technology Limited | Eritromicinas y procedimiento para su preparacion. |
| PT956034E (pt) | 1996-07-30 | 2002-12-31 | Novartis Ag | Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina |
| WO1998009972A1 (en) * | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
| CA2286311A1 (en) * | 1997-04-09 | 1998-10-15 | Isotechnika, Inc. | Method for production of antibodies to specific sites of rapamycin |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| WO1999064040A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
| GB9814006D0 (en) | 1998-06-29 | 1998-08-26 | Biotica Tech Ltd | Polyketides and their synthesis |
| GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
| US6150513A (en) | 1998-09-16 | 2000-11-21 | Kosan Biosciences, Inc. | Polyketide synthase enzymes and recombinant DNA constructs therefor |
| MXPA01003376A (es) * | 1998-10-02 | 2002-11-07 | Kosan Biosciences Inc | Enzimas policetido sintetasa y construcciones de acido desoxirribonucleico recombinante para las mismas. |
| SE516023C2 (sv) | 1999-06-24 | 2001-11-12 | Abb Ab | Industrirobot innefattande en växellådskonfiguration samt förfarande i en industrirobot |
| CA2377918A1 (en) | 1999-07-09 | 2001-01-18 | Bruce G. Gold | Compositions and methods for promoting nerve regeneration |
| US6569867B2 (en) * | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
| DE60033965T2 (de) | 1999-10-29 | 2008-01-10 | Kosan Biosciences, Inc., Hayward | Rapamycin analoge |
| AU4858801A (en) | 2000-04-13 | 2001-10-30 | Biotica Tech Ltd | Hybrid glycosylated products and their production and use |
| CA2407259A1 (en) * | 2000-05-17 | 2001-11-22 | Chaitan Khosla | Polyketide derivatives |
| GB0019986D0 (en) | 2000-08-14 | 2000-10-04 | Biotica Tech Ltd | Polyketides and their synthesis |
| US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
| GB0128680D0 (en) | 2001-11-29 | 2002-01-23 | Biotica Tech Ltd | Hybrid glycosylated products and their production and use |
| PT1478648E (pt) * | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| CA2621093A1 (en) | 2002-07-16 | 2004-01-22 | Biotica Technology Limited | Production of polyketides and other natural products |
| AU2007237187B2 (en) | 2002-07-16 | 2010-08-05 | Biotica Technology Limited | Production of polyketides |
| GB0216509D0 (en) | 2002-07-16 | 2002-08-28 | Biotica Tech Ltd | Production of polyketides and other natural products |
| CA2492153C (en) * | 2002-07-16 | 2012-05-08 | Biotica Technology Limited | Production of polyketide fkbp-ligand analogues |
-
2003
- 2003-07-16 CA CA2492153A patent/CA2492153C/en not_active Expired - Fee Related
- 2003-07-16 ES ES03764029.9T patent/ES2544624T3/es not_active Expired - Lifetime
- 2003-07-16 EP EP05075774A patent/EP1589031B1/en not_active Expired - Lifetime
- 2003-07-16 EP EP05077470A patent/EP1655372A3/en not_active Withdrawn
- 2003-07-16 US US10/497,135 patent/US7300942B2/en not_active Expired - Lifetime
- 2003-07-16 EP EP08075113A patent/EP1967520A2/en not_active Withdrawn
- 2003-07-16 DK DK05075774T patent/DK1589031T3/da active
- 2003-07-16 AT AT05075774T patent/ATE370161T1/de active
- 2003-07-16 EP EP03764029.9A patent/EP1521828B1/en not_active Expired - Lifetime
- 2003-07-16 DE DE60315723T patent/DE60315723T2/de not_active Expired - Lifetime
- 2003-07-16 CN CNB038169169A patent/CN100569944C/zh not_active Expired - Fee Related
- 2003-07-16 WO PCT/GB2003/003230 patent/WO2004007709A2/en not_active Ceased
- 2003-07-16 JP JP2004520912A patent/JP2005532809A/ja active Pending
- 2003-07-16 BR BR0312691-9A patent/BR0312691A/pt not_active IP Right Cessation
- 2003-07-16 ES ES05075774T patent/ES2296063T3/es not_active Expired - Lifetime
- 2003-07-16 AU AU2003246965A patent/AU2003246965B2/en not_active Ceased
- 2003-07-16 PT PT05075774T patent/PT1589031E/pt unknown
- 2003-07-16 EP EP10179385A patent/EP2277898A3/en not_active Withdrawn
- 2003-07-16 MX MXPA05000139A patent/MXPA05000139A/es active IP Right Grant
-
2005
- 2005-11-08 US US11/269,215 patent/US20060078980A1/en not_active Abandoned
-
2007
- 2007-07-16 US US11/778,264 patent/US7390895B2/en not_active Expired - Lifetime
- 2007-07-16 US US11/778,319 patent/US7645768B2/en not_active Expired - Fee Related
- 2007-10-15 CY CY20071101328T patent/CY1107764T1/el unknown
- 2007-10-31 US US11/931,474 patent/US20080287482A1/en not_active Abandoned
-
2008
- 2008-02-07 JP JP2008028177A patent/JP4751899B2/ja not_active Expired - Fee Related
- 2008-02-07 JP JP2008028178A patent/JP2008200039A/ja not_active Ceased
-
2009
- 2009-11-09 JP JP2009255660A patent/JP2010075187A/ja not_active Withdrawn
-
2011
- 2011-03-11 US US13/046,304 patent/US9040259B2/en not_active Expired - Lifetime
-
2014
- 2014-04-09 JP JP2014080591A patent/JP2014176384A/ja active Pending
-
2015
- 2015-03-02 US US14/635,979 patent/US9605001B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312691A (pt) | Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo | |
| Atanasov et al. | Natural products in drug discovery: advances and opportunities | |
| Dinglasan et al. | Microbial secondary metabolites: advancements to accelerate discovery towards application | |
| Carrell et al. | Novel metabolic interactions and environmental conditions mediate the boreal peatmoss-cyanobacteria mutualism | |
| Xu et al. | Recent advances in the applications of promoter engineering for the optimization of metabolite biosynthesis | |
| Delmotte et al. | An integrated proteomics and transcriptomics reference data set provides new insights into the Bradyrhizobium japonicum bacteroid metabolism in soybean root nodules | |
| Zhang et al. | Unlocking the trove of metabolic treasures: activating silent biosynthetic gene clusters in bacteria and fungi | |
| Baunach et al. | Harnessing the potential: advances in cyanobacterial natural product research and biotechnology | |
| Keasling | Synthetic biology and the development of tools for metabolic engineering | |
| Radek et al. | Miniaturized and automated adaptive laboratory evolution: evolving Corynebacterium glutamicum towards an improved d-xylose utilization | |
| Gan et al. | A combined cell‐free transcription‐translation system from Saccharomyces cerevisiae for rapid and robust protein synthe | |
| Liao et al. | Unexpected extensive lysine acetylation in the trump-card antibiotic producer Streptomyces roseosporus revealed by proteome-wide profiling | |
| van Dolleweerd et al. | MIDAS: a modular DNA assembly system for synthetic biology | |
| King et al. | Accessing Nature’s diversity through metabolic engineering and synthetic biology | |
| Ishida et al. | Assembly and absolute configuration of short‐lived polyketides from Burkholderia thailandensis | |
| Tenhaef et al. | Automated rational strain construction based on high-throughput conjugation | |
| WO2020247803A2 (en) | Frameshift suppressor trna compositions and methods of use | |
| Pilpel | Noise in biological systems: pros, cons, and mechanisms of control | |
| Zhang et al. | Synthetic biology of cyanobacteria | |
| Li | Next-generation synthetic biology approaches for the accelerated discovery of microbial natural products | |
| Li et al. | Rational construction of genome-minimized Streptomyces host for the expression of secondary metabolite gene clusters | |
| Augustijn et al. | Prediction of gene cluster function based on transcriptional regulatory networks uncovers a novel locus required for desferrioxamine B biosynthesis | |
| Breitling et al. | Synthetic biology approaches to actinomycete strain improvement | |
| Li et al. | Genetic mining of the “dark matter” in fungal natural products | |
| Kang et al. | Production of phenylacetyl-homoserine lactone analogs by artificial biosynthetic pathway in Escherichia coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |